Cellectar Biosciences
CLRB
14 hedge funds and large institutions have $1.82M invested in Cellectar Biosciences in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 0 closing their positions.
288% more capital invested
Capital invested by funds: $469K → $1.82M (+$1.35M)
75% more funds holding
Funds holding: 8 → 14 (+6)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$737K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$567K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
| 4 |
VF
Virtu Financial
New York
|
+$58.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$1K |
CLRB Hedge Fund Activity: Q4 2017 in Review
14 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2017, worth a combined $1.82M — up 288% from $469K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CLRB positions and 0 closed out — a net gain of 6 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $737K. The largest seller was Northwestern Mutual Wealth Management, cutting an estimated $1K.
- 14 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2017, up from 8 in Q3 2017.
- Funds reported $1.82M of Cellectar Biosciences stock for Q4 2017, up 288% quarter-over-quarter.
- 6 funds opened new Cellectar Biosciences positions in Q4 2017 and 0 closed out, a net change of +6 holders.
- The largest Cellectar Biosciences buyer in Q4 2017 was Susquehanna International Group, an estimated $737K added.
- The largest Cellectar Biosciences seller in Q4 2017 was Northwestern Mutual Wealth Management, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2017.